Technological Advances in Radiation Oncology for Central Nervous System Tumors

Seminars in Radiation Oncology

Volumn 19, Issue 3, 2009, Pages 179-186

  Noda, Shin ei ^a   Lautenschlaeger, Tim ^a   Siedow, Michael R ^a   Patel, Disha R ^a   El Jawahri, Areej ^a   Suzuki, Yoshiyuki ^b   Loeffler, Jay S ^a   Bussiere, Marc R ^a   Chakravarti, Arnab ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GUNMA UNIVERSITY   (Japan)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

BRACHYTHERAPY; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYBERKNIFE; GLIOBLASTOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; NEUTRON CAPTURE THERAPY; PARTICLE RADIATION; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; REVIEW; STEREOTACTIC RADIOSURGERY; X RAY;

BRACHYTHERAPY; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, COMPUTER-ASSISTED;

EID: 65649145152     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.02.006     Document Type: Review

References (75)

1. Chan M.F., Schupak K., Burman C., et al. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim 28 (2003) 261-265
2. Hermanto U., Frija E.K., Lii M.J., et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: Does IMRT increase the integral dose to normal brain?. Int J Radiat Oncol Biol Phys 67 (2007) 1135-1144
3. Samuelsson A.J.K. Intensity modulated radiotherapy treatment planning for dynamic multileaf collimator delivery: Influence of different parameters on dose distributions. Int J Radiat Oncol Biol Phys 66 (2003) 19-28
4. Al-Ghazi M., Kuo J., Ramsinghani N., et al. Irvine, University of California experience with tomotherapy using the Peacock system. Med Dosim 26 (2001) 17-27
5. Voynov G., Kaufman S., Hong T., et al. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 25 (2002) 606-611
6. Narayana A., Yamada J., Berry S., et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64 (2006) 892-897
7. Sultanem K., Patrocinio H., Lambert C., et al. The use of hypofractionated intensitymodulated irradiation in the treatment of glioblastoma multiforme: Preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58 (2004) 247-252
8. Fuller C.D., Choi M., Forthuber B., et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiol Oncol 2 (2007) 26-33
9. Panet-Raymond V., Souhami L., Roberge D., et al. Accelerated hypofractionated intensity-modulated radiotherapy with Concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: A safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73 (2008) 473-478
10. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102 (1951) 316-319
11. Nedzi L.A. The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: Observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol 18 (2008) 265-272
12. Hasegawa T., Kondziolka D., Flickinger J.C., et al. Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy?. Neurosurgery 52 (2003) 1318-1326
13. Shehata M.K., Young B., Reid B., et al. Stereotatic radiosurgery of 468 brain metastases < or =2 cm: Implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys 59 (2004) 87-93
14. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. J Am Med Assoc 295 (2006) 2483-2491
15. Sneed P.K., Lamborn K.R., Forstner J.M., et al. Radiosurgery for brain metastases: Is whole brain radiotherapy necessary?. Int J Radiat Oncol Biol Phys 43 (1999) 549-558
16. Alexander III E., Moriarty T.M., Davis R.B., et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87 (1995) 34-40
17. Joseph J., Adler J.R., Cox R.S., et al. Linear accelerator-based stereotaxic radiosurgery for brain metastases: The influence of number of lesions on survival. J Clin Oncol 14 (1996) 1085-1092
18. Breneman J.C., Warnick R.E., Albright Jr. R.E., et al. Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series. Cancer 79 (1997) 551-557
19. Shaw E., Scott C., Souhami L., et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47 (2000) 291-298
20. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004) 1665-1672
21. Kondziolka D., Patel A., Lunsford L.D., et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45 (1999) 427-434
22. Chougule P.B., Burton-Williams M., Saris S., et al. Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys 48 Suppl 1 (2000) 114
23. Sanghavi S.N., Miranpuri S.S., Chappell R., et al. Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51 (2001) 426-434
24. Wang L.G., Guo Y., Zhang X., et al. Brain metastasis: Experience of the Xi-Jing Hospital. Stereotact Funct Neurosurg 78 (2002) 70-83
25. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
26. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. J Am Med Assoc 280 (1998) 1485-1489
27. Patel M., Siddiqui F., Jin J.Y., et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neuro Oncol 92 (2008) 185-191
28. Schwer A.L., Damek D.M., Kavanagh B.D., et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70 (2008) 993-1001
29. Lipani J.O., Jackson P.S., Soltys S.G., et al. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme. Technol Cancer Res Treat 7 (2008) 249-255
30. Schulz-Ertner D., Jakel O., and Schlegel W. Radiation therapy with charged particles. Semin Radiat Oncol 16 (2006) 249-259
31. Hall E. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1-7
32. Fitzek M.M., Thornton A.F., Harsh G., et al. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: Results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys 51 (2001) 131-137
33. Fitzek M.M., Thornton A.F., Rabinov J.D., et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg 91 (1999) 251-260
34. Schulz-Ertner D., and Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 25 (2007) 953-964
35. Ando K., Koike S., Ohira C., et al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75 (1999) 505-512
36. Nakano T., Suzuki Y., Ohno T., et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res 12 (2006) 2185-2190
37. In: Griffin T.W. (Ed). Particle-Beam Radiation Therapy (1992), J.B. Lippincott, Philadelphia, PA
38. Mizoe J.E., Tsujii H., Hasegawa A., et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: Combined X-ray radiotherapy, chemotherapy and carbon in radiotherapy. Int J Radiat Oncol Biol Phys 69 (2007) 390-396
39. Yamamoto T., Nakai K., and Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett 262 (2008) 143-152
40. Barth R.F., Coderre J.A., Vicente M.G., et al. Boron neutron capture therapy of cancer: Current status and future prospects. Clin Cancer Res 11 (2005) 3987-4002
41. Chanana A.D., Capala J., Chadha M., et al. Boron neutron capture therapy for glioblastoma multiforme: Interim results from the phase I/II dose-escalation studies. Neurosurgery 44 (1999) 1182-1192
42. Busse P.M., Harling O.K., Palmer M.R., et al. A critical examination of the results from the Harvard-mit NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neuro Oncol 62 (2003) 111-121
43. Diaz A.Z. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neuro Oncol 62 (2003) 101-109
44. Yamamoto T., Matsumura A., Nakai K., et al. Current clinical results of the Tsukuba BNCT trial. Appl Radiol Isot 61 (2004) 1089-1093
45. Wittig A., Hideghéty K., Paquis P., et al. Current clinical results of the EORTC-study. In: Surewein W., and Wittig A. (Eds). Research and Development in Neutron Capture Therapy (2002), Monduzzi Editore, Bologna 11961 RM
46. Capala J., Stenstam B.H., Skold K., et al. Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol 62 (2003) 135-144
47. Coderre J.A., Hopewell J.W., Turcottea J.C., et al. Tolerance of normal human brain to boron neutron capture therapy. Appl Rad Isot 61 (2004) 1083-1087
48. Carlsson J., Kulberg E.B., Capala J., et al. Ligand liposomes and boron neutron capture therapy. J Neurooncol 62 (2003) 47-59
49. Ceberg C.P., Brun A., Kahl S.B., et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J Neurosurg 83 (1995) 86-92
50. Kabalka G.W., and Yao M.L. Synthesis of a potential boron neutron capture therapy agent: 1-aminocyclobutane-1-carboxylic acid bearing a butylboronic acid side chain. Synthesis 18 (2003) 2890-2893
51. Diaz A., Laramore G., Wiersema R., et al. Pharmachology studies of Na2B10H10 (GB-10) in human tumor patients. In: Surewein W., and Wittig A. (Eds). Research and Development in Neutron Capture Therapy (2002), Monduzzi Editore, Bologna 993-999
52. Tietze L.F., Griesbach U., Bothe U., et al. Novel carboranes with a DNA binding unit for the treatment of cancer by boron neutron capture therapy. Chembiochem 3 (2002) 219-225
53. Tietze L.F., Griesbach U., Schuberth I., et al. Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy. Chem Eur J 9 (2003) 1296-1302
54. El-Zaria M.E., Dörfler U., and Gabel D. Synthesis of (aminoalkylamine)-N-aminoalkyl)azanonaborane(11) derivatives for boron neutron capture therapy. J Med Chem 45 (2002) 5817-5819
55. Tjarks W. The use of Boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. J Organomet Chem 614-615 (2001) 37-47
56. Al-Madhoun A.S., Johnsamuel J., Yan J., et al. Synthesis of a small library of 3-(carboranylalkyl) thymidinesan d their biological evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 45 (2002) 4018-4028
57. Woodhouse S.L. Synthesis and DNA binding properties of dinuclear platinum(II)-amine complexes of 1,7-dicarba-closo-dodecaborane(12). Chem Commun 7 (2001) 2464-2465
58. Olejiniczak A.B., Koziolkiewicz M., and Lesnikowski Z.J. Carboranyl oligonucleotides. 4. Synth And Physicochem Stud of Oligonucleotides Containing:20-O(o-carboran-1- yl)methyl group. Antisense Nucleic Acid Drug Dev 12 (2002) 79-94
59. Ivanov D., Bachovchin W.W., and Redfield A.G. Boron-11 pure quadrupole resonance investigation of peptide boronic acid inhibitors bound to a-lyticprotease. Biochemistry 41 (2002) 1587-1590
60. Gutin P.H., Phillips T.L., Wara W.M., et al. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg 60 (1984) 61-68
61. Selker R.G., Shapiro W.R., Burger P., et al. The Brain Tumor Cooperative Group NIH trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51 (2002) 343-357
62. Gutin P.H., Leibel S.A., Wara W.M., et al. Recurrent malignant gliomas: Survival following interstitial brachytherapy with high activity iodine-125 sources. J Neurosurg 67 (1987) 864-873
63. Bernstein M., Laperrier N., Glen J., et al. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30 (1994) 1213-1217
64. Gutin P.H., Hosobuchi Y., Phillips T.L., et al. Stereotactic interstitial irradiation for the treatment of tumors. Cancer Treat Rep 65 (1981) 103-106
65. Hosobuchi Y., Phillips T.L., Stupar T.A., et al. Interstitial brachytherapy of primary brain tumors: Preliminary report. J Neurosurg 53 (1980) 613-617
66. Hitchon P.W., VanGlider J.C., Wen B.C., et al. Brachytherapy for malignant recurrent and untreated gliomas. Stereotact Funct Neurosurg 59 (1992) 174-178
67. Gutin P.H., Prados M.D., Phillips T.L., et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21 (1991) 601-606
68. Laperriere N.J., Leung P.M., McKenzie S., et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 41 (1998) 1005-1011
69. Loeffler J.S., Alexander E., Hochberg F.H., et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 19 (1990) 1455-1462
70. Levin V.A., Wara W.M., Gutin P.H., et al. Initial Anal of NCOG:6G, 82-81: Bromodeoxyuridine (BUdR) during irradiation followed by CCNU, procarbazine, and vincristine (PCV) chemotherapy for malignant glioma. Proc Am Soc Clin Oncol 9 (1990) 91
71. Deutsch M., Green S.B., Strike T.A., et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the post-operative treatment of malignant gliomas (BTSG 77-02). Int J Radiat Oncol Biol Phys 16 (1989) 1389-1396
72. Frankel R., Stubbs J., Dillehay D., et al. Pre-clinical evaluation of a novel device for delivering brachytherapy to resected brain tumor cavity margins. Int J Radiat Oncol Biol Phys 45 Suppl 1 (1999) 319-320
73. Dempsey J.F., Williams J.A., Stubbs J.B., et al. Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain tumor resection-cavity margins. Int J Radiat Oncol Biol Phys 42 (1998) 421-429
74. Monroe J.I., Dempsey J.F., Dorton J.A., et al. Experimental validation of dose calculation algorithms for the GliaSite RTS, a novel 125I liquid-filled balloon brachytherapy applicator. Med Phys 28 (2001) 73-85
75. Tatter S.B., Shaw E.G., Rosenblum M.L., et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite radiation therapy system) for treatment of recurrent malignant glioma: Multicenter safety and feasibility trial. J Neurosurg 99 (2003) 297-303